
Peter Schraml

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2436156/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nature Communications, 2012, 3, 811.	12.8	227
2	Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncolmmunology, 2018, 7, e1378844.	4.6	179
3	PD‣1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. International Journal of Cancer, 2016, 139, 396-403.	5.1	151
4	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nature Medicine, 2017, 23, 1046-1054.	30.7	145
5	Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Modern Pathology, 2009, 22, 31-36.	5.5	104
6	Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment. Nature Cancer, 2022, 3, 122-133.	13.2	92
7	Decentral gene expression analysis for ER+/Her2â^' breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 251-259.	2.8	88
8	pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 889-898.	7.0	55
9	Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. Neoplasia, 2019, 21, 247-256.	5.3	55
10	Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer, 2016, 16, 638.	2.6	47
11	MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. Oncotarget, 2016, 7, 78433-78447.	1.8	45
12	Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 409-418.	2.8	42
13	Detailed simulation of cancer exome sequencing data reveals differences and common limitations of variant callers. BMC Bioinformatics, 2017, 18, 8.	2.6	40
14	Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma. European Urology Focus, 2021, 7, 152-162.	3.1	34
15	ILâ€8 and CXCR1 expression is associated with cancer stem cellâ€like properties of clear cell renal cancer. Journal of Pathology, 2019, 248, 377-389.	4.5	32
16	Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 2012, 28, 654-658.	2.6	29
17	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. Breast Cancer Research, 2017, 19, 55.	5.0	29
18	Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses than Seen in the Eosinophilic Subtype. Cancers, 2019, 11, 1492.	3.7	28

PETER SCHRAML

#	Article	IF	CITATIONS
19	Clear cell renal cell carcinoma with wildâ€ŧype <i>von Hippel‣indau</i> gene: a nonâ€existent or new tumour entity?. Histopathology, 2019, 74, 60-67.	2.9	27
20	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nature Communications, 2021, 12, 7033.	12.8	27
21	Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants. JAMA Surgery, 2019, 154, e190484.	4.3	26
22	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Nature Communications, 2021, 12, 734.	12.8	26
23	Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. BMC Cancer, 2012, 12, 310.	2.6	25
24	Cancer Sample Biobanking at the Next Level: Combining Tissue With Living Cell Repositories to Promote Precision Medicine. Frontiers in Cell and Developmental Biology, 2019, 7, 246.	3.7	24
25	Spatially multiplexed RNA in situ hybridization to reveal tumor heterogeneity. Nucleic Acids Research, 2020, 48, e17-e17.	14.5	23
26	Quantitative microimmunohistochemistry for the grading of immunostains on tumour tissues. Nature Biomedical Engineering, 2019, 3, 478-490.	22.5	22
27	Loss of CDKN1A mRNA and Protein Expression Are Independent Predictors of Poor Outcome in Chromophobe Renal Cell Carcinoma Patients. Cancers, 2020, 12, 465.	3.7	21
28	Scavenger receptor BI promotes cytoplasmic accumulation of lipoproteins in clear-cell renal cell carcinoma. Journal of Lipid Research, 2018, 59, 2188-2201.	4.2	16
29	Allele Loss and Reduced Expression of CYCLOPS Genes is a Characteristic Feature of Chromophobe Renal Cell Carcinoma. Translational Oncology, 2019, 12, 1131-1137.	3.7	16
30	Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer. Modern Pathology, 2019, 32, 1042-1052.	5.5	16
31	Liquid Biopsies in Renal Cell Carcinoma—Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease. Frontiers in Oncology, 2020, 10, 582843.	2.8	16
32	Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer. BMC Genomics, 2015, 16, 247.	2.8	15
33	The DNA hypermethylation phenotype of colorectal cancer liver metastases resembles that of the primary colorectal cancers. BMC Cancer, 2020, 20, 290.	2.6	13
34	<i>VHL</i> missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma. Oncotarget, 2017, 8, 10199-10212.	1.8	11
35	Tissue lithography: Microscale dewaxing to enable retrospective studies on formalin-fixed paraffin-embedded (FFPE) tissue sections. PLoS ONE, 2017, 12, e0176691.	2.5	10
36	Spatial Distribution of Private Gene Mutations in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 2163.	3.7	10

PETER SCHRAML

#	Article	IF	CITATIONS
37	Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma. Oncolmmunology, 2015, 4, e1049805.	4.6	8
38	CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2016, 22, 6069-6077.	7.0	8
39	MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers, 2022, 14, 1763.	3.7	8
40	Cytoplasmic ADP-ribosylation levels correlate with markers of patient outcome in distinct human cancers. Modern Pathology, 2021, 34, 1468-1477.	5.5	7
41	The synergism of spatial metabolomics and morphometry improves machine learningâ€based renal tumour subtype classification. Clinical and Translational Medicine, 2022, 12, e666.	4.0	7
42	Statistical tests for intra-tumour clonal co-occurrence and exclusivity. PLoS Computational Biology, 2021, 17, e1009036.	3.2	6
43	Frequent Germline and Somatic Single Nucleotide Variants in the Promoter Region of the Ribosomal RNA Gene in Japanese Lung Adenocarcinoma Patients. Cells, 2020, 9, 2409.	4.1	4
44	Discretization of Gene Expression Data Unmasks Molecular Subgroups Recurring in Different Human Cancer Types. PLoS ONE, 2016, 11, e0161514.	2.5	4
45	Mapping Spatial Genetic Landscapes in Tissue Sections through Microscale Integration of Sampling Methodology into Genomic Workflows. Small, 2021, 17, 2007901.	10.0	3
46	Immunohistochemical detection of CD3 in T-cell lymphomas: superior sensitivity of rabbit monoclonal 2GV6 antibody compared to mouse monoclonal F7·2·38 antibody. Journal of Histotechnology, 2012, 35, 175-179.	0.5	2
47	Spatial protein heterogeneity analysis in frozen tissues to evaluate tumor heterogeneity. PLoS ONE, 2021, 16, e0259332.	2.5	2
48	The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer Journal of Clinical Oncology, 2017, 35, e15083-e15083.	1.6	0